River & Mercantile Asset Management LLP grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 256.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,600 shares of the biopharmaceutical company’s stock after buying an additional 40,000 shares during the period. River & Mercantile Asset Management LLP’s holdings in Bristol-Myers Squibb were worth $3,543,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC increased its position in shares of Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the last quarter. Greenleaf Trust increased its position in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 39 shares during the last quarter. Finally, Keel Point LLC increased its position in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Co (NYSE BMY) traded up $0.34 during mid-day trading on Friday, reaching $62.81. The company’s stock had a trading volume of 5,489,081 shares, compared to its average volume of 5,400,000. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a twelve month low of $46.01 and a twelve month high of $66.10. The stock has a market capitalization of $102,800.00, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. equities research analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.
Several research firms have recently commented on BMY. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a report on Thursday, December 28th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $65.05.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/river-mercantile-asset-management-llp-purchases-40000-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.